Slide
Securing
Connections
IMPORTANT NOTICE OF PROPOSED SETTLEMENT OF STOCKHOLDER
DERIVATIVE LAWSUIT.
Bushansky & Houlihan v. Kawas, et al., Case No. 2:22-cv-497 TSZ (W.D. Wash.)
Please click here for important information regarding this proposed settlement
of stockholder derivative lawsuit, including important notices, written objection
deadline, and Zoom meeting information for the Final Approval Hearing scheduled
for July 18, 2024 at 10:30 a.m. pacific standard time.
Corporate Profile
We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, fosgonimeton (ATH-1017), a novel small molecule, for Alzheimer’s, Parkinson's disease dementia and dementia with Lewy bodies.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Latest Presentations
January 8, 2024
Events & Presentations
May 13, 2024 from 1:30 PM to 1:55 PM EDT
December 6, 2023 from 12:15 PM to 12:45 PM EST
November 16, 2023 from 1:00 PM to 1:25 PM GMT